Research advances in targeting claudin 18.2 in pancreatic ductal adenocarcinoma treatment

doi:10.3748/wjg.122906

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 45

This Article

(3)

(2)

(0)

(18)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Dec 7, 2026; 32(45): 122906
Published online Dec 7, 2026. doi: 10.3748/wjg.122906

Table 2 Summary of research progress on claudin 18.2-targeting drugs in pancreatic cancer

Drug class	Drug name	Company	Indications	Clinical testing phase	Registration number
mAb	Zolbetuximab	Astellas Pharma/Baxter Oncology GmbH	CLDN18.2-positive metastatic pancreatic adenocarcinoma/pancreatic adenocarcinoma	2	CTR20220914
	Zolbetuximab	Astellas Pharma Global Development, Inc.	Pancreatic adenocarcinoma metastatic/CLDN18.2-positive pancreatic adenocarcinoma	1	NCT06396091
	FG-M108	FutureGen Biopharmaceutical Co., Ltd.	Pancreatic cancer	3	NCT07383922/CTR20260995
	Osemitamab	Suzhou Transcenta Therapeutics Co., Ltd.	PDAC	2	NCT04495296
	Osemitamab	Bristol Myers Squibb Co.	Pancreatic cancer	2	NCT04396821
	ASKB589	Jiangsu Aosaikang Biomedicine Co., Ltd.	Pancreatic cancer	2	CTR20202121
	AB-011	CARsgen Therapeutics Co., Ltd.	Pancreatic adenocarcinoma	1	NCT04400383
	FL-301	Flame Biosciences LLC	Pancreatic cancer	2	NCT05181865
ADC	CMG901 (AZD0901)	Astra Zeneca PLC	PDAC	2	NCT06219941
	CMG901 (AZD0901)	Keymed Biomedical Technology (Chengdu) Co. Ltd.	Pancreatic cancer	1	NCT04805307
	ATG-022	Antengene (Hangzhou) Biologics Co. Ltd.	Pancreatic cancer	Preclinical	FDA
	BL-M05D1	Systimmune, Inc.	Advanced PDAC	1	NCT07021066
	SHR-A1904	Shanghai HengruiPharmaceutical Co., Ltd.	Advanced pancreatic adenocarcinoma	1	CTR20211290
	IBI343	InnoventBiologics (Suzhou) Co., Ltd.	PDAC	1	NCT5458219
			PDAC	1	NCT05458219
			Pancreatic cancer	3	NCT07066098
	E0-3021	CSPC Pharmaceutical Group Ltd./Elevation Oncology, Inc.	Pancreatic cancer	1	The details of the drug have not been disclosed
ADC	XNW27011	Evopoint Biosciences Co., Ltd.	Metastatic pancreatic adenocarcinoma	2	NCT06792435
	JS107	Shanghai Junshi Biosciences Co., Ltd.	Pancreatic cancer	1	CTR20223134/NCT05657418
	LM-302	LaNova Medicines (Zhejiang) Co., Ltd.	Pancreatic cancer	3	The details of the drug have not been disclosed
	SOT-102	SOTIO Biotech as	Advanced pancreatic adenocarcinoma/pancreatic adenocarcinoma	2	NCT05525286
	SOT-102	Excoso as	Pancreatic cancer	2	The details of the drug have not been disclosed
CAR-T	IMC-008	Suzhou Immunofoco Biotechnology Co., Ltd.	Pancreatic cancer	The details of the drug have not been disclosed	FDA
	SENL-215	Hebei Senlangbio Biotechnology Co., Ltd.	Pancreatic cancer	Preclinical	The details of the drug have not been disclosed
	DCTY-1502	Beijing Dingcheng Peptide Source Biotech Co., Ltd.	Pancreatic cancer	Preclinical	The details of the drug have not been disclosed
BsAb	SNG2002	Beijing Shenogen Pharma Group Ltd.	Pancreatic cancer	Preclinical	The details of the drug have not been disclosed
BsAb	QLS31905	Qilu Pharmaceutical Co., Ltd.	Pancreatic cancer	3	NCT07079228

mAb: Monoclonal antibodies; ADC: Antibody drug conjugates; BsAb: Bispecific antibodies; CAR-T: Chimeric antigen receptor T cell; CLDN18.2: Claudin 18.2; PDAC: Pancreatic ductal adenocarcinoma; FDA: United States Food and Drug Administration; CTR: Clinical trial registration; NCT: National clinical trial.

Full Size Table

Citation: Wei YH, Zhang SC, Guan BJ, Jian JN, Li CG, Wang ZK, Qu HR, Li ZG, Liu MY, Wang JT. Research advances in targeting claudin 18.2 in pancreatic ductal adenocarcinoma treatment. World J Gastroenterol 2026; 32(45): 122906
URL: https://www.wjgnet.com/1007-9327/full/v32/i45/122906.htm
DOI: https://dx.doi.org/10.3748/wjg.122906

Wei YH, Zhang SC, Guan BJ, Jian JN, Li CG, Wang ZK, Qu HR, Li ZG, Liu MY, Wang JT. Research advances in targeting claudin 18.2 in pancreatic ductal adenocarcinoma treatment. World J Gastroenterol 2026; 32(45): 122906 [DOI: 10.3748/wjg.122906]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.